Valeurs seuils pour le rapport coût-efficacité en soins de santé - KCE

KCE reports 100 ICER Thresholds 63
24. Briggs A. Economics notes: handling uncertainty in economic evaluation. BMJ.
25.
1999;319(7202):120.
Briggs A, Sculpher M, Buxton M. Uncertainty in the economic evaluation of health care
technologies: the role of sensitivity analysis. Health Econ. 1994;3(2):95-104.
26. Groot Koerkamp B, Hunink MGM, Stijnen T, Hammitt JK, Kuntz KM, Weinstein MC.
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.[see
comment]. Medical Decision Making. 2007;27(2):101-11.
27. Torgerson DJ, Raftery J. Economic notes. Discounting. BMJ. 1999;319(7214):914-5.
28. Krahn M, Gafni A. Discounting in the economic evaluation of health care interventions. Med
Care. 1993;31(5):403-18.
29. Ganiats TG. Prevention, policy, and paradox: what is the value of future health? Am J Prev Med.
1997;13(1):12-7.
30. Milne R. Valuing prevention: discounting health benefits and costs in New Zealand. N Z Med J.
2005;118(1214):U1443.
31. Bonneux L, Birnie E. The discount rate in the economic evaluation of prevention: a thought
experiment. J Epidemiol Community Health. 2001;55(2):123-5.
32. Brouwer W, van Hout B, Rutten F. A fair approach to discounting future effects: taking a
societal perspective. J Health Serv Res Policy. 2000;5(2):114-8.
33. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs
and health effects in cost effectiveness analyses. BMJ. 2005;331(7514):446-8.
34. Claxton K, Sculpher M, Culyer A, McCabe C, Briggs A, Akehurst R, et al. Discounting and
cost-effectiveness in NICE - stepping back to sort out a confusion. Health Econ. 2006;15(1):1-
4.
35. Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness
analysis. Health Econ. 2001;10(7):587-99.
36. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations:
stepping forward towards optimal decision rules. Health Econ. 2007;16(3):307-17.
37. Philips Z, Claxton K, Palmer S. The half-life of truth: what are appropriate time horizons for
research decisions? Med Decis Making. 2008;28(3):287-99.
38. Walker D, Fox-Rushby J. Allowing for uncertainty in economic evaluations: qualitative
sensitivity analysis. Health Policy Plan. 2001;16(4):435-43.
39. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health
Econ. 2007;16(2):195-209.
40. Fenwick E, Claxton K, Sculpher M. The value of implementation and the value of information:
combined and uneven development. Med Decis Making. 2008;28(1):21-32.
41. Claxton K, Ginnelly L, Sculpher M, Philips Z, Palmer S. A pilot study on the use of decision
theory and value of information analysis as part of the NHS Health Technology Assessment
programme. Health Technol Assess. 2004;8(31):1-103, iii.
42. Briggs A, Gray AM. Handling uncertainty when performing economic evaluation of healthcare
interventions. Health Technology Assessment. 1999;3(2).
43. Culyer AJ, Newhouse JP. Handbook of Health Economics. New York: Elsevier; 2000.
44. Dolan P, Edlin R, Tsuchiya A. The relative societal value of health gains to different
beneficiaries. 2008. RM03/JH11 Available from:
45.
http://www.pcpoh.bham.ac.uk/publichealth/methodology/projects/RM03_JH11_PD.shtml
Weinstein M, Zeckhauser R. Critical ratios and efficient allocation. Journal of Public Economics.
1973;2:147-57.
46. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for
answers. Pharmacoeconomics. 2006;24(11):1121-31.
47. Sendi P, Gafni A, Birch S. Opportunity costs and uncertainty in the economic evaluation of
health care interventions. Health Econ. 2002;11(1):23-31.
48. National Institute for Clinical Excellence. Briefing paper for the Methods Working Party on the
Cost-Effectiveness Threshold. 2007.
49. Birch S, Gafni A. Economics and the evaluation of health care programmes: generalisability of
methods and implications for generalisability of results. Health Policy. 2003;64(2):207-19.